Media coverage about Mesa Laboratories (NASDAQ:MLAB) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesa Laboratories earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the medical instruments supplier an impact score of 44.9392740838606 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s rankings:

MLAB has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $169.00 target price for the company in a research note on Tuesday, May 23rd. BidaskClub lowered shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a research note on Monday, July 31st.

Shares of Mesa Laboratories (NASDAQ:MLAB) traded down 3.34% during midday trading on Friday, hitting $131.67. 35,780 shares of the stock were exchanged. The stock has a market cap of $494.95 million, a price-to-earnings ratio of 45.25 and a beta of 0.46. Mesa Laboratories has a 12 month low of $102.14 and a 12 month high of $169.80. The firm’s 50-day moving average is $143.91 and its 200-day moving average is $136.02.

Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by $0.17. Mesa Laboratories had a return on equity of 6.12% and a net margin of 6.69%. The business had revenue of $22.67 million for the quarter, compared to analysts’ expectations of $22.90 million. Equities research analysts predict that Mesa Laboratories will post $2.72 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 31st will be issued a dividend of $0.16 per share. The ex-dividend date is Tuesday, August 29th. This represents a $0.64 annualized dividend and a dividend yield of 0.49%. Mesa Laboratories’s dividend payout ratio (DPR) is presently 22.94%.

In related news, Director H Stuart Campbell sold 1,000 shares of the firm’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $136.58, for a total transaction of $136,580.00. Following the completion of the transaction, the director now owns 45,976 shares of the company’s stock, valued at $6,279,402.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Glenn E. Adriance sold 4,000 shares of the firm’s stock in a transaction on Friday, June 9th. The stock was sold at an average price of $148.98, for a total transaction of $595,920.00. Following the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at approximately $1,489,800. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,150 shares of company stock valued at $2,996,919. 17.00% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/13/mesa-laboratories-nasdaqmlab-given-daily-media-sentiment-score-of-0-11.html.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.